Foghorn Therapeutics (FHTX) Expected to Announce Earnings on Monday

Foghorn Therapeutics (NASDAQ:FHTX) is anticipated to post its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect Foghorn Therapeutics to post earnings of ($0.28) per share and revenue of $6.1970 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Monday, November 3, 2025 at 9:30 AM ET.

Foghorn Therapeutics (NASDAQ:FHTX) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.03. The firm had revenue of $7.56 million for the quarter, compared to analysts’ expectations of $7.62 million. On average, analysts expect Foghorn Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Foghorn Therapeutics Stock Up 4.4%

FHTX opened at $4.07 on Monday. Foghorn Therapeutics has a 52 week low of $2.94 and a 52 week high of $9.70. The stock’s fifty day moving average is $4.85 and its two-hundred day moving average is $4.75. The company has a market capitalization of $230.08 million, a P/E ratio of -3.42 and a beta of 3.03.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in FHTX. Raymond James Financial Inc. grew its stake in Foghorn Therapeutics by 6.7% during the 2nd quarter. Raymond James Financial Inc. now owns 2,367,292 shares of the company’s stock worth $11,126,000 after buying an additional 148,940 shares during the last quarter. Geode Capital Management LLC grew its stake in Foghorn Therapeutics by 16.9% during the 2nd quarter. Geode Capital Management LLC now owns 807,674 shares of the company’s stock worth $3,797,000 after buying an additional 116,979 shares during the last quarter. Ameriprise Financial Inc. purchased a new position in Foghorn Therapeutics during the 2nd quarter worth $528,000. Bridgeway Capital Management LLC grew its stake in Foghorn Therapeutics by 63.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 64,100 shares of the company’s stock worth $301,000 after buying an additional 25,000 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in Foghorn Therapeutics during the 2nd quarter worth $102,000. 61.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

FHTX has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Foghorn Therapeutics in a report on Saturday. B. Riley initiated coverage on Foghorn Therapeutics in a report on Wednesday, September 17th. They issued a “buy” rating and a $10.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $11.00.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.